<![CDATA[Servier 보도자료 - 뉴스와이어]]>https://www.newswire.co.kr/?md=A10&act=article&no=33773>Sun, 24 May 2026 10:19:34 +0900Copyright (c) 2004~2026 Korea Newswire All rights reservedko-KR<![CDATA[Servier and Taiho Oncology Present Overall Survival Data for Trifluridine/Tipiracil (LONSURF®) In Combination With Bevacizumab in Patients With Refractory Metastatic Colorectal Cancer at 2023 ASCO Gastrointestinal Cancers Symposium]]>https://www.newswire.co.kr/newsRead.php?no=959941Wed, 18 Jan 2023 09:25:00 +0900<![CDATA[Analysis of Patients With Prior Gastrectomy Treated With LONSURF® (trifluridine/tipiracil) Published in JAMA Oncology]]>https://www.newswire.co.kr/newsRead.php?no=895533Tue, 15 Oct 2019 09:29:24 +0900<![CDATA[Servier acquires non-Hodgkin B-cell lymphoma treatment PIXUVRI® (pixantrone) from CTI BioPharma, strengthening the Servier oncology portfolio]]>https://www.newswire.co.kr/newsRead.php?no=894951Tue, 01 Oct 2019 16:29:03 +0900